论文部分内容阅读
应用免疫组化方法检测了41例肺癌和30例癌旁组织中C-erbB-2P185的表达。结果发现肺癌及癌旁组织中C-erbB-2P185表达率分别为63.41％和10.00％,二者差异显著(P0.05);C-erbB-2P185表达与肺癌病理分级、TNM分期及肺门和(或)纵隔淋巴结转移(简称分级、分期及转移)均有关(P<0.05)。提示C-erbB-2与肺癌发生、发展有关,可作为评估肺癌生物学行为及预后的指标。
Immunohistochemistry was used to detect the expression of C-erbB-2P185 in 41 cases of lung cancer and 30 cases of adjacent tissues. The results showed that the expression rates of C-erbB-2P185 were 63.41% and 10.00% in lung cancer and adjacent tissues, respectively. There was a significant difference between them (P<0.05). The expression rates of C-erbB-2P185 in squamous cell carcinoma and adenocarcinoma were 54.17% and 75.00%, there was no significant difference between the two (P> 0.05); C-erbB-2P185 expression and lung cancer pathological grade, TNM staging and hilar and (or) mediastinal lymph node metastasis (referred to as classification, staging and metastasis) are related (P<0.05). It suggests that C-erbB-2 is related to the occurrence and development of lung cancer, and it can be used as an index to evaluate the biological behavior and prognosis of lung cancer.